PIK3CA mutation in non-metastatic triple-negative breast cancer as a potential biomarker of early relapse: A case report

• Autores: Valencia, GA, Rioja, P, Morante, Z, Araujo, JM, Vallejos, HD, Guerra, H, Gomez, Henry L
• Formato: artículo
• Fecha de Publicación: 2021
• Institución: Instituto Nacional de Enfermedades Neoplásicas
• Repositorio: INEN-Institucional
• Lenguaje: inglés
• OAI Identifier: oai:repositorio.inen.sld.pe:20.500.14703/86
• Enlace del recurso: https: //doi.org/10.5306/wjco.v12.i8.702; https://hdl.handle.net/20.500.14703/86
• Nivel de acceso: acceso abierto
• Materia: Biomarker; Case report; Early relapse; Liquid biopsy; PIK3CA mutation; Triple-negative breast cancer; https://purl.org/pe-repo/ocde/ford#3.02.21

Background: Currently, the detection of PIK3CA mutations is of special interest in personalized medicine because it is frequently found in triple-negative breast cancer (TNBC). The PI3KCA mutation is an independent negative prognostic factor for survival in metastatic breast cancer, and its prognostic value in liquid biopsy as a biomarker of treatment and early relapse is under investigation, both for metastatic disease and neoadjuvant scenario with curative intent. Case summary: A 54-year-old female patient with TNBC clinical stage IIIA, who, after receiving neoadjuvant chemotherapy (based on anthracyclines and taxanes), surgery, radiotherapy, and adjuvant capecitabine, was detected with a PI3KCA mutation in tissue and peripheral blood (ctDNA in liquid biopsy). After 10 mo, the patient had disease relapse of left cervical node disease. Conclusion: The detection of PIK3CA mutation in TNBC after neoadjuvant treatment might be associated with early relapse or rapid disease progression.